Patients in test won't get drug, Amgen decides.
Pollack
Andrew
A
D002986:Clinical Trials as Topic / Q000191:economics; D004345:Drug Industry / Q000191:economics / Q000941:ethics; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D004739:England; D051100:Glial Cell Line-Derived Neurotrophic Factor; D006801:Humans; D007629:Kentucky; D009414:Nerve Growth Factors / Q000009:adverse effects / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D015990:Placebo Effect; D016079:Refusal to Treat / Q000941:ethics; D012107:Research Design; D035842:Research Subjects; D014481:United States
D015507:Drugs, Investigational; C495039:GDNF protein, human; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors